Investigational drug · Phase 2
KH658
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Age-related Macular Degeneration.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "KH658"
First trial start
2024
Jun 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KH658", any sponsor or status.
Conditions studied
As listed on its trial records.
- Age-related Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "KH658" as an intervention, largest first.
Chengdu Origen Biotechnology Co., Ltd.Industry
NCT06458595 · 44 participants (planned) · Start Jun 28, 2024 · Primary completion Mar 31, 2026
Drug: KH658 · For: Age-related Macular Degeneration
Sites: Tianjin, China
- A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular DegenerationActive, not recruiting
Chengdu Origen Biotechnology Co., Ltd.Industry
NCT06825858 · 9 participants (planned) · Start Apr 7, 2025 · Primary completion Jan 2027
Drug: KH658 · For: Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Lemont, Illinois; Memphis, Tennessee
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Age-related Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- OpRegenPhase 22 trials
Roche (Genentech) · Age-Related Macular Degeneration, Geographic Atrophy
- ABBV-6628Phase 21 trial
AbbVie · Geographic Atrophy, Age-Related Macular Degeneration
- KH631Phase 21 trial
Chengdu Origen Biotechnology Co., Ltd. · Age-Related Macular Degeneration
- SOM-401Phase 21 trial
Inflammasome Therapeutics · Geographic Atrophy, Age-Related Macular Degeneration
- VOY-101Phase 21 trial
Perceive Biotherapeutics, Inc. · Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.